HCP
IONS icon

Hexagon Capital Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Hexagon Capital Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9
Closed -$272 – 872
2025
Q1 		$272 Buy
+9
New +$295 ﹤0.01% 1727
2023
Q1 		– Sell
-9
Closed -$340 – 1476
2022
Q4 		$340 Hold
9
– – ﹤0.01% 1342
2022
Q3 		$0 Hold
9
– – ﹤0.01% 1368
2022
Q2 		$0 Hold
9
– – ﹤0.01% 1211
2022
Q1 		$0 Buy
+9
New +$295 ﹤0.01% 949

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Hexagon Capital Partners's IONS Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Ionis Pharmaceuticals (IONS) in Q2 2025, closing a stake of 9 shares — an estimated $272 sold.

Hexagon Capital Partners first reported a position in IONS in Q1 2022 and held it in 5 quarters. The position peaked at $340 in Q4 2022. 362 funds tracked by Wall St. Rank hold IONS as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Ionis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 9 Ionis Pharmaceuticals shares in Q2 2025, an estimated $272.
  • Hexagon Capital Partners first reported a position in Ionis Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • Hexagon Capital Partners's Ionis Pharmaceuticals position peaked at $340 in Q4 2022.
  • 362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.